Human Anti-APP Recombinant Antibody (clone 266) (CAT#: HPAB-1640-FY)

Figure 1 Brain injection and clearance of 125I-Aβ1-40 after peripheral administration of anti-Aβ antibodies in mice.

Timecourseofelimination of 125I-A from brains 120 h after intraperitoneal administration of 10D5, 266, or LB509 as a control IgG.

Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., ... & Iwatsubo, T. (2009). Aβ immunotherapy: intracerebral sequestration of Aβ by an anti-Aβ monoclonal antibody 266 with high affinity to soluble Aβ. Journal of Neuroscience, 29(36), 11393-11398.

Figure 2 Brain injection and clearance of 125I-Aβ1-40 after peripheral administration of anti-Aβ antibodies in mice.

The remaining 125I-A at 60 min after microinjection of 125I-Aβ at 1, 24, or 120 h after intraperitoneal administration of 266 or LB509.

Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., ... & Iwatsubo, T. (2009). Aβ immunotherapy: intracerebral sequestration of Aβ by an anti-Aβ monoclonal antibody 266 with high affinity to soluble Aβ. Journal of Neuroscience, 29(36), 11393-11398.

Figure 3 Differential extraction of brains of APP transgenic mice following peripheral administration of anti-Aβ antibodies.

The levels of monomer Aβ1-40 in the RIPA fractions of 4-month-old A7 mice 120 h after intraperitoneal administration of 266 or LB509 were quantitated by ELISA with (shaded) or without (blank) immunodepletion by protein G.

Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., ... & Iwatsubo, T. (2009). Aβ immunotherapy: intracerebral sequestration of Aβ by an anti-Aβ monoclonal antibody 266 with high affinity to soluble Aβ. Journal of Neuroscience, 29(36),1393-11398.

Figure 4 Differential extraction of brains of APP transgenic mice following peripheral administration of anti-Aβ antibodies.

The levels of monomer Aβ1-42 in the RIPA fractions of 4-month-old A7 mice 120 h after intraperitoneal administration of 266 or LB509 were quantitated by ELISA with (shaded) or without (blank) immunodepletion by protein G.

Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., ... & Iwatsubo, T. (2009). Aβ immunotherapy: intracerebral sequestration of Aβ by an anti-Aβ monoclonal antibody 266 with high affinity to soluble Aβ. Journal of Neuroscience, 29(36),1393-11398.

Figure 5 The total Aβ and its precursor C99 in the RIPA fractions were analyzed by immunoblotting with 82E1 after immunoprecipitation with the same antibody.

Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., ... & Iwatsubo, T. (2009). Aβ immunotherapy: intracerebral sequestration of Aβ by an anti-Aβ monoclonal antibody 266 with high affinity to soluble Aβ. Journal of Neuroscience, 29(36),1393-11398.

Figure 6 Chronic administration of anti-Aβ mAbs increased plasma Aβ levels in J20 mice.

Free Aβ1-x, i.e. material still present in the supernatant following PrG incubation, was significantly increased in J20 mice that received 1C22, compared to 46-4- and m266-treated J20 mice.

Mably, A. J., Liu, W., Mc Donald, J. M., Dodart, J. C., Bard, F., Lemere, C. A., ... & Walsh, D. M. (2015). Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice. Neurobiology of disease, 82, 372-384.

Figure 7 Chronic administration of anti-Aβ mAbs increased plasma Aβ levels in J20 mice.

Antibody-bound Aβ1-x was significantly increased in m266-treated J20 mice, compared to 46-4- and 1C22-treated J20 mice.

Mably, A. J., Liu, W., Mc Donald, J. M., Dodart, J. C., Bard, F., Lemere, C. A., ... & Walsh, D. M. (2015). Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice. Neurobiology of disease, 82, 372-384.